Atlas Trials

Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Clinical trial NCT05319028 · TERMINATED

Trial details

NCT number
NCT05319028
Sponsor
Calithera Biosciences, Inc
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Non-GCB/ABC Diffuse Large B-Cell LymphomaWith and Without MyD88 and/or CD79B Mutations
Start date
2022-06-23
Primary completion
2023-02-24
Enrollment
2

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.